Herceptin and the heart--a molecular modifier of cardiac failure.
Chien
Kenneth R
KR
Cardiovascular Research Center, Massachusetts General Hospital, Boston, USA.
D048868:Adaptor Proteins, Signal Transducing; D000818:Animals; D018943:Anthracyclines / Q000009:adverse effects; D000911:Antibodies, Monoclonal / Q000009:adverse effects* / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D001943:Breast Neoplasms / Q000188:drug therapy*; D002352:Carrier Proteins / Q000378:metabolism; D018734:Genes, erbB-2; D006321:Heart / Q000187:drug effects; D006331:Heart Diseases / Q000139:chemically induced; D006333:Heart Failure / Q000139:chemically induced*; D006801:Humans; D047908:Intracellular Signaling Peptides and Proteins; D051379:Mice; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000276:immunology*; D015398:Signal Transduction; D000068878:Trastuzumab
D048868:Adaptor Proteins, Signal Transducing; D018943:Anthracyclines; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D002352:Carrier Proteins; D047908:Intracellular Signaling Peptides and Proteins; D018719:Erb-b2 Receptor Tyrosine Kinases; D000068878:Trastuzumab; C413364:ERBIN protein, human; C498804:Erbb2ip protein, mouse